EA201991305A1 - Производные тирозина и композиции, включающие их - Google Patents

Производные тирозина и композиции, включающие их

Info

Publication number
EA201991305A1
EA201991305A1 EA201991305A EA201991305A EA201991305A1 EA 201991305 A1 EA201991305 A1 EA 201991305A1 EA 201991305 A EA201991305 A EA 201991305A EA 201991305 A EA201991305 A EA 201991305A EA 201991305 A1 EA201991305 A1 EA 201991305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tyrosine hydroxylase
compositions including
hydroxylase inhibitor
tyrosine derivatives
including theirs
Prior art date
Application number
EA201991305A
Other languages
English (en)
Russian (ru)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed filed Critical
Publication of EA201991305A1 publication Critical patent/EA201991305A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EA201991305A 2016-11-30 2017-11-30 Производные тирозина и композиции, включающие их EA201991305A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
EA201991305A1 true EA201991305A1 (ru) 2019-10-31

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991305A EA201991305A1 (ru) 2016-11-30 2017-11-30 Производные тирозина и композиции, включающие их

Country Status (12)

Country Link
EP (1) EP3548086A1 (cg-RX-API-DMAC10.html)
JP (2) JP2019536783A (cg-RX-API-DMAC10.html)
KR (1) KR20190089191A (cg-RX-API-DMAC10.html)
CN (1) CN110062633A (cg-RX-API-DMAC10.html)
AU (1) AU2017368135A1 (cg-RX-API-DMAC10.html)
BR (1) BR112019011033A2 (cg-RX-API-DMAC10.html)
CA (1) CA3045110A1 (cg-RX-API-DMAC10.html)
EA (1) EA201991305A1 (cg-RX-API-DMAC10.html)
IL (1) IL266840A (cg-RX-API-DMAC10.html)
MX (1) MX2019006326A (cg-RX-API-DMAC10.html)
PH (1) PH12019501186A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018102506A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
KR20220099990A (ko) 2019-11-07 2022-07-14 인3바이오 리미티드 비티로신 표적화 키나아제 억제제와 병용하여 성장 인자 항체를 사용하기 위한 방법 및 조성물
CN115515575A (zh) * 2020-01-17 2022-12-23 迪美公司 用于调节癌症的酪氨酸衍生物
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
EP3075247B1 (en) * 2004-02-02 2022-10-12 BioSight Ltd. Conjugates for cancer therapy and diagnosis
DK2013221T3 (en) * 2006-04-19 2015-09-28 Univ Texas Compositions and methods for cellular imaging and therapy
EP2190429B1 (en) * 2007-09-10 2016-04-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2013109610A1 (en) * 2012-01-17 2013-07-25 Steven Hoffman Pharmaceutical compositions and methods
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
JP2022153587A (ja) 2022-10-12
EP3548086A1 (en) 2019-10-09
JP2019536783A (ja) 2019-12-19
CN110062633A (zh) 2019-07-26
IL266840A (en) 2019-07-31
KR20190089191A (ko) 2019-07-30
AU2017368135A1 (en) 2019-06-13
WO2018102506A1 (en) 2018-06-07
MX2019006326A (es) 2019-07-12
PH12019501186A1 (en) 2020-02-10
BR112019011033A2 (pt) 2019-10-15
CA3045110A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
MY195110A (en) Antibodies to PD-1 and uses Thereof
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
MX2017013613A (es) Neoepitodos de cancer.
JOP20190285A1 (ar) استخدام الجسم المضاد لمضاد cd70 argx-110 في معالجة سرطان الدم النخاعي الحاد
JOP20200016B1 (ar) أجسام مضادة لـ cd137
BR112015020290A2 (pt) métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
EA201991555A1 (ru) Композиции и способы усиления или увеличения продукции ifn i типа
MX2016011619A (es) Anticuerpos anti-egfrviii y usos de los mismos.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
PH12017501748B1 (en) Antibodies to icos
MX2016012097A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer.
BR112017008914A2 (pt) método para tratar câncer, composição e uso da composição
PH12019501186A1 (en) Tyrosine derivatives and composition comprising them
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
EA201890895A1 (ru) Мультивалентные и моновалентные мультиспецифические комплексы и их применение
CR20110553A (es) Terapia complementaria contra el cáncer
MX387296B (es) Proliferacion ex vivo de celulas epiteliales.
BR112013006331A2 (pt) composições de fulvestranto e métodos de uso
UY35787A (es) Composiciones útiles para tratar trastornos relacionados con kit
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
EP4414035A3 (en) Combined preparations for the treatment of cancer